Is Cefazolin Inferior to Nafcillin for Treatment of Methicillin-Susceptible Staphylococcus aureus Bacteremia?
Open Access
- 1 November 2011
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 55 (11), 5122-5126
- https://doi.org/10.1128/aac.00485-11
Abstract
About 20% of methicillin-susceptible Staphylococcus aureus (MSSA) isolates have a substantial inoculum effect with cefazolin, suggesting that cefazolin treatment may be associated with clinical failure for serious MSSA infections. There are no well-matched controlled studies comparing cefazolin with nafcillin for the treatment of MSSA bacteremia. A retrospective propensity-score-matched case-control study was performed from 2004 to 2009 in a tertiary care hospital where nafcillin was unavailable from August 2004 to August 2006. The cefazolin group (n = 49) included MSSA-bacteremic patients treated with cefazolin during the period of nafcillin unavailability, while the nafcillin group (n = 84) comprised those treated with nafcillin. Treatment failure was defined as a composite outcome of a change of antibiotics due to clinical failure, relapse, and mortality. Of 133 patients, 41 patients from each group were matched by propensity scores. There were no significant differences in baseline characteristics between the matched groups. The treatment failure rates were not significantly different at 4 or 12 weeks (10% [4/41] versus 10% [4/41] at 4 weeks [P > 0.99] and 15% [6/41] versus 15% [6/41] at 12 weeks [P > 0.99]). Cefazolin treatment was interrupted less frequently than nafcillin treatment due to drug adverse events (0% versus 17%; P = 0.02). Cefazolin had clinical efficacy similar to that of nafcillin and was more tolerable than nafcillin for the treatment of MSSA bacteremia.This publication has 13 references indexed in Scilit:
- Are all beta-lactams similarly effective in the treatment of methicillin-sensitive Staphylococcus aureus bacteraemia?Clinical Microbiology & Infection, 2011
- Inoculum Effect with Cefazolin among Clinical Isolates of Methicillin-Susceptible Staphylococcus aureus : Frequency and Possible Cause of Cefazolin Treatment FailureAntimicrobial Agents and Chemotherapy, 2009
- Outcome of Vancomycin Treatment in Patients with Methicillin-SusceptibleStaphylococcus aureusBacteremiaAntimicrobial Agents and Chemotherapy, 2008
- Staphylococcus aureus Native Valve Infective Endocarditis: Report of 566 Episodes from the International Collaboration on Endocarditis Merged DatabaseClinical Infectious Diseases, 2005
- Infective EndocarditisCirculation, 2005
- Evaluation of the Efficacy and Safety of Outpatient Parenteral Antimicrobial Therapy for Infections With Methicillin-sensitive Staphylococcus aureusSouthern Medical Journal, 2005
- Relapse of Type A -Lactamase-Producing Staphylococcus aureus Native Valve Endocarditis during Cefazolin Therapy: Revisiting the IssueClinical Infectious Diseases, 2003
- Staphylococcus aureus Bacteremia: Predictors of 30-Day Mortality in a Large CohortClinical Infectious Diseases, 2000
- Surgical wound infection rates by wound class, operative procedure, and patient risk indexAmerican Journal Of Medicine, 1991
- Clinical Experiences with Cefazolin and Other Cephalosporins in Bacterial EndocarditisThe Journal of Infectious Diseases, 1973